Agenus (NASDAQ:AGEN) Rating Lowered to “Hold” at Zacks Research

Agenus (NASDAQ:AGEN) was downgraded by Zacks Research from a “strong-buy” rating to a “hold” rating in a research note issued to investors on Monday,Zacks.com reports.

Separately, Wall Street Zen raised Agenus from a “hold” rating to a “buy” rating in a research note on Monday, April 6th. One equities research analyst has rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $14.50.

Agenus Trading Up 5.5%

Shares of NASDAQ:AGEN opened at $3.44 on Monday. The stock has a market capitalization of $132.10 million, a P/E ratio of 2.16 and a beta of 1.60. The business has a 50-day moving average price of $3.72 and a two-hundred day moving average price of $3.67. Agenus has a 1-year low of $2.71 and a 1-year high of $7.34.

Agenus (NASDAQ:AGEN) last announced its quarterly earnings results on Monday, May 11th. The biotechnology company reported $1.02 EPS for the quarter, missing analysts’ consensus estimates of $2.10 by ($1.08). The company had revenue of $33.70 million during the quarter, compared to the consensus estimate of $129.50 million. Agenus had a net margin of 50.49% and a negative return on equity of 29.79%. As a group, equities analysts predict that Agenus will post 2.1 EPS for the current year.

Institutional Investors Weigh In On Agenus

Several large investors have recently made changes to their positions in the stock. Redwood Family Wealth LLC acquired a new stake in shares of Agenus in the 4th quarter valued at approximately $44,000. Ovata Capital Management Ltd bought a new position in Agenus during the 4th quarter worth $97,000. Virtu Financial LLC bought a new position in Agenus during the 4th quarter worth $108,000. EP Wealth Advisors LLC bought a new position in Agenus during the 4th quarter worth $31,000. Finally, Quadrature Capital Ltd bought a new position in shares of Agenus in the fourth quarter worth $54,000. Institutional investors and hedge funds own 61.46% of the company’s stock.

Agenus Company Profile

Agenus, Inc (NASDAQ:AGEN) is a clinical-stage immuno-oncology company headquartered in Lexington, Massachusetts. The company focuses on the discovery and development of therapies designed to modulate the immune system’s response to cancer. Leveraging proprietary platforms in checkpoint modulation, vaccine technology and adjuvant systems, Agenus aims to deliver combination regimens that enhance antitumor activity across a variety of solid tumors and hematological malignancies.

Agenus’ pipeline includes monoclonal antibodies targeting immune checkpoints, cytokine-based therapeutics and vaccine candidates built on its engineered heat shock protein (HSP) platform.